Determination of nimodipine in human plasma by HPLC-ESI-MS and its application to a bioequivalence study

Journal of Chromatographic Science

Volumn 48, Issue 2, 2010, Pages 81-85

  Zhao, Ying ^a,b   Zhai, Desheng ^c,d   Chen, Xijing ^a   Yu, Qiaoling ^a   He, Hui ^a   Sun, Ya ^a   Gao, Zidong ^a,e   Wang, Lei ^a   Wang, Huanhuan ^a   Han, De'en ^a   Ji, Hui ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Xiuxiang Medical University   (China)

^e HENAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 75849154703     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/48.2.81     Document Type: Article

References (14)

1. M. Langley and E. Sorkin. Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease. Drugs. 37: 669-699 (1989).
2. S. Keyrouz and M. Diringer. Clinical review: Prevention and therapy of vasospasm in subarachnoid hemorrhage. Crit Care. 11: 220 (In press) (2007)
3. M. Sobrado, M. López, F. Carceller, A. García, and J. Roda. Combined nimodipine and citicoline reduce infarct size, attenuate apoptosis and increase bcl-2 expression after focal cerebral ischemia. Neuroscience. 118: 107-113 (2003).
4. J. López and J. Birks. Nimodipine for primary degenerative, mixed and vascular dementia. Cochrane Database Syst Rev. 3: CD000147(2002);.
5. P. Jakobsen, E. Mikkelsen, J. Laursen and F. Jensen. Determination of nimodipine by gas chromatography using electron-capture detection; external factors influencing nimodipine concentrations during intravenous administration. J. Chromatogr. 374: 383-387 (1986).
6. M. Rosseel, M. Bogaert and L. Huyghens. Determination of the calcium antagonist nimodipine in plasma by capillary gas chromatography and nitrogen detection. J. Chromatogr. 533: 224-228 (1990).
7. M. Qian and J. Gallo. High-performance liquid chromatographic determination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr. 578: 316-320 (1992).
8. J. López, V. Martínez, R. Alonso, and R. Jiménez. High-performance liquid chromatography with amperometric detection applied to the screening of 1,4-dihy-dropyridines in human plasma. J. Chromatogr A 870: 105-114 (2000).
9. Z. He, D. Zhong, X. Chen, X. Liu, X. Tang, and L. Zhao. Development of a dissolution medium for nimodipine tablets based on bioavailability evaluation. Eur J. Pharm. Sci. 21: 487-491 (2004).
10. F. Qiu, X. Chen, X. Li, and D. Zhong. Determination of nimodipine in human plasma by a sensitive and selective liquid chromatography-tandem mass spectrometry method. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 802: 291-297 (2004).
11. F. Qin, Y. Ma, Y. Wang, L. Chen, D. Wang, and F. Li. Determination of nimodipine in human plasma by ultra performance liquid chromatography-tandem mass spectrometry and pharmacokinetic application. J. Pharm. Biomed. Anal. 46: 557-562 (2008)
12. FDA Guidance for Industry, Bioanalytical Method Validation, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), http://www.fda.gov/cder/guidance/index.htm (2001).
13. FDA Guidance for Industry, Statistical Approaches to Establishing Bioequivalence, US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), http://www.fda.gov/cder/guidance/index.htm (2001).
14. Blardi P, Urso R, De Lalla A, Volpi L, Perri TD, and Auteri A. Nimodipine: drug pharmacokinetics and plasma adenosine levels in patients affected by cerebral ischemia. Clin. Pharmacol. Ther. 72: 556-561 (2002).